Last updated: May 23, 2026
Suppliers for Ethinyl Estradiol and Norethindrone (API, Intermediates, and Finished Dose Manufacturers)
Supplier selection for ethinyl estradiol (EE) plus norethindrone (NE) depends on what you are buying: API, key intermediates, or finished-dose tablets. EE and NE are widely sourced global commodities with layered compliance requirements (GMP, DMF support for FDA filings, impurity controls, and polymorph/particle-size targets for tablets). The supplier universe also varies by geography and regulatory footprint, because US FDA approvals and DMF status determine what can be used for abbreviated pathways and what can be filed for safety/CMC support.
Who supplies ethinyl estradiol and norethindrone APIs in the US and EU?
The most decision-relevant suppliers are those that (1) can support regulatory submissions through controlled filings (DMFs in the US, CEPs/DMFs elsewhere), (2) operate in GMP regimes aligned with FDA/EU expectations, and (3) have documented capability for steroid APIs and downstream tablet manufacture.
Ethinyl estradiol API: common supplier profiles
- Steroid API manufacturers and contract API producers with historical supply for hormonal contraceptives.
- Firms that produce EE with tight control of key impurities that are scrutinized in hormonal combination products.
Norethindrone API: common supplier profiles
- Steroid API suppliers with capability for NE crystallinity and impurity specifications tailored to oral tablets.
- Firms that can align particle size and polymorph with blend performance for fixed-dose combinations.
Which companies make finished-dose tablets containing ethinyl estradiol and norethindrone?
Finished-dose supply is typically organized around:
- Proprietary brands and authorized generics in the US market
- Multi-source generic tablets for 1 mg/0.02 mg, 0.5 mg/0.035 mg, 0.4 mg/0.035 mg, and similar fixed-dose ratios (varies by product)
Finished-dose manufacturing is concentrated among large CDMOs and generic-drug manufacturers that run oral solid dose lines with high inspection readiness.
What API suppliers support US FDA DMFs for ethinyl estradiol and norethindrone?
For US market participants, the practical test is whether the API supplier can provide DMF reference support (or a compatible alternative dossier path) and reproducible CMC packages for the specific API grade and impurity profile.
- US DMFs determine what can be cross-referenced in ANDAs for combination products.
- Steroid APIs often require detailed impurity disclosure and tighter characterization than many non-steroid molecules.
Which suppliers provide ethinyl estradiol and norethindrone as intermediates or custom synthesis?
For vertical integration or cost takeout, some manufacturers source from:
- Intermediate-stage steroid suppliers (custom conversion steps to reach EE and NE)
- Specialized steroid CDMOs that run controlled synthesis with EHS and GMP alignment for APIs
This matters for businesses using contract manufacturing where a single finished-dose maker wants consistent upstream material and impurity control across batches.
How to evaluate whether an ethinyl estradiol/norethindrone supplier is audit-ready for GMP?
Shortlist suppliers using objective criteria tied to regulatory CMC risk:
- GMP certification status for API manufacture
- Documented batch-to-batch consistency and release testing frequency
- Steroid-specific impurity control system (including genotoxicity-relevant impurities if applicable to the route)
- Stability program coverage that matches your proposed shelf life
- Supply continuity, including redundancy for key synthesis steps
What manufacturing/IP constraints affect sourcing of ethinyl estradiol and norethindrone?
Even for widely used hormonal steroids, supplier choice can be constrained by:
- Site-specific regulatory history (inspection outcomes)
- Proprietary know-how in intermediate steps that can become locked to certain buyers
- Batch release specifications tied to a particular tablet formulation (blend uniformity and dissolution targets)
How does supplier choice affect generic entry risk for EE/NE combination tablets?
Generic launch risk rises when:
- The generic relies on an API source with weaker DMF support for impurities or particle specs
- The API grade differs from what the finished-dose formulation was optimized for
- The manufacturer’s tablet process cannot reliably match dissolution and content uniformity
For fixed-dose hormonal products, CMC matching is a frequent friction point, especially if supplier changes force reformulation.
What are the typical market ratios and how does that affect supplier selection?
Supplier selection is usually ratio-driven because it determines:
- Tablet strength specification and acceptable content uniformity bands
- Binder/lubricant system and granulation approach
- Dissolution targets that must be met consistently
Common label strengths for EE/NE combinations vary by regimen. Your sourcing strategy should match the exact strengths in the targeted product label and the tablet platform used by the intended manufacturer.
Timeline: when does supplier exclusivity or regulatory exclusivity end for EE/NE combos?
For generic EE/NE fixed-dose products, exclusivity is mostly product- and NDA-specific, not API-wide. Exclusionary risk is typically determined by:
- Listed patents for each specific formulation, method-of-use, or regimen
- Orange Book coverage for the branded or first-generic reference product
- Pediatric exclusivity and new formulation patent estates (if applicable)
Because EE/NE are established therapies, most entry timing risk comes from product-specific listed patents and the readiness of the ANDA/Chemistry package, not from API exclusivity.
Patent and Orange Book considerations that determine which suppliers can qualify
Even when APIs are commodity-like, eligibility to support a generic NDA can depend on:
- DMF cross-reference acceptance by the ANDA filer
- Patent-landscape outcomes for each dosage form and regimen
- Any formulation patents that affect dissolution requirements and therefore acceptable API grades
Which jurisdictions matter most for global EE/NE supply chains?
For commercial planning:
- FDA-aligned dossiers govern US marketability for ANDA/505(b)(2) filings
- EU and UK approvals drive cost-competitive sourcing for EU/UK launches
- GMP equivalence and inspection outcomes determine speed to qualification for CDMOs
For many brands and generics, India, China, and EU-based producers are common origins, with the limiting factor being dossier support and inspection history.
Competitive landscape: API suppliers vs tablet manufacturers vs CDMOs
A common operational model:
- API supply: one or more API producers with DMF support
- Finished dose: tablet manufacturer or CDMO that buys APIs and runs blending, granulation, compression, coating, and QC release
- Regulatory support: CMC team aligns API specifications, cleaning validation, and tablet process controls to the intended submission
Supplier changes often force revalidation of tablet processing parameters. That is the practical barrier, not the availability of the molecule.
Key questions to ask internally before finalizing an EE/NE supplier
- Is the supplier’s API grade compatible with your tablet formulation approach without reformulation?
- Does the supplier have a stable impurity profile consistent with your ANDA development strategy?
- Can the supplier provide documentation needed for your CMC package (specs, CoA patterns, validation reports, stability)?
- Can the finished-dose manufacturer qualify the incoming material quickly without extending development timelines?
Key Takeaways
- EE plus NE is widely supplied at the API and finished-dose levels, but qualification hinges on GMP readiness and regulatory dossier support.
- The practical differentiator is DMF/CMC compatibility, steroid impurity control, and reproducibility that matches tablet dissolution/content-uniformity targets.
- For generic and lifecycle strategy, supplier selection is tied to patent-landscape and Orange Book coverage of the specific EE/NE product, because formulation and regimen patents can constrain acceptable manufacturing changes.
FAQs
- How do DMF-supported ethinyl estradiol and norethindrone APIs reduce ANDA CMC risk?
- What tablet strength combinations of ethinyl estradiol and norethindrone are most sensitive to API particle size and dissolution matching?
- How do impurity specifications for ethinyl estradiol and norethindrone differ by supplier and affect release testing?
- What audit focus areas drive qualification of steroid API suppliers for fixed-dose oral contraceptive tablets?
- Which manufacturing changes are most likely to trigger process revalidation for EE/NE tablet formulations when switching API sources?
References
- US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
- US FDA. Drug Master Files (DMF). FDA. https://www.fda.gov/drugs/drug-master-files-dmfs
